Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation.
OBJECTIVE
Endogenous hyperthyroidism is associated with altered coagulation. The aim of the present study is to investigate the effect of levothyroxine (LT(4)) suppression treatment for benign thyroid nodules on coagulation system.


METHODS
Prospective case-control study. Patients Thirty consecutive euthyroid pre-menopausal women with nodular goitre disease and 28 healthy controls were included in the study.


METHODS
Plasma fibrinogen, d-dimer, von Willebrand factor (vWF), tissue factor (TF), tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and tissue factor pathway inhibitor (TFPI) levels were measured at baseline and after LT(4) suppression therapy.


RESULTS
Plasma levels of fibrinogen, d-dimer, vWF, TF and PAI-1 increased significantly after treatment with LT(4) for 1 year. Serum FT(4) was a significant predictor of increased fibrinogen, vWF and PAI-1 levels, when the data was controlled for age and BMI.


CONCLUSIONS
Our results suggest that LT(4) suppression therapy for benign thyroid nodules is associated with enhanced coagulation.
Demir
Tevfik
T
Department of Internal Medicine, Division of Endocrinology and Metabolism, Dokuz Eylul University, Izmir, Turkey.
Akinci
Baris
B
Comlekci
Abdurrahman
A
Karaoglu
Oguzhan
O
Ozcan
Mehmet Ali
MA
Yener
Serkan
S
Yuksel
Faize
F
Secil
Mustafa
M
Yesil
Sena
S
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D016022:Case-Control Studies; D015536:Down-Regulation; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006042:Goiter; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011446:Prospective Studies; D016606:Thyroid Nodule / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013974:Thyroxine / Q000008:administration & dosage*
D017395:Plasminogen Activator Inhibitor 1; D005340:Fibrinogen; D013974:Thyroxine